Free Trial

Harmony Biosciences (HRMY) Earnings Date, Estimates & Call Transcripts

Harmony Biosciences logo
$35.62 -0.29 (-0.81%)
Closing price 05/20/2025 04:00 PM Eastern
Extended Trading
$35.16 -0.46 (-1.30%)
As of 08:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harmony Biosciences Earnings Summary

Harmony Biosciences issued Q1 2025 earnings on May 6, 2025, reporting an EPS of $0.78, which beat the consensus estimate of $0.59 by $0.19. Quarterly revenue rose 19.5% year-over-year to $184.73 million, above the consensus estimate of $184.26 million. With a trailing EPS of $2.62 and a P/E Ratio of 16.88, Harmony Biosciences' earnings are expected to grow 27.98% next year, from $2.43 to $3.11 per share.

Upcoming Q2
Earnings Date
Aug. 5Before Market OpensEstimated
Consensus EPS
(May. 6)
$0.59
Actual EPS
(May. 6)
$0.78 Beat By $0.19
Actual Revenue
(May. 6)
$184.73M

Q1 2025 Earnings Resources

HRMY Upcoming Earnings

Harmony Biosciences' next earnings date is estimated for Tuesday, August 5, 2025, based on past reporting schedules.

Get Harmony Biosciences Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Harmony Biosciences and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

HRMY Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

HRMY Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Harmony Biosciences Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue Guidance
Q1 20251$0.78$0.78$0.78
Q2 20251$0.87$0.87$0.87
Q3 20251$1.03$1.03$1.03
Q4 20251$1.10$1.10$1.10

Harmony Biosciences Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/5/2025
(Estimated)
--------
5/6/2025Q1 2025$0.59$0.78+$0.19$0.78$184.26M$184.73M
2/25/2025Q4 2024$0.74$0.85+$0.11$0.85$201.25M$201.30M
10/29/2024Q3 2024$0.64$0.79+$0.15$0.79$184.07M$186.00M
8/6/2024Q2 2024-$0.04$0.20+$0.24$0.20$172.53M$172.80M
4/30/2024Q1 2024$0.60$0.67+$0.07$0.67$154.10M$154.62M
2/22/2024Q4 2023$0.74$0.45 -$0.29$0.45$168.90M$168.40M
10/31/2023Q3 2023$0.67$0.63 -$0.04$0.63$147.83M$160.30M
8/1/2023Q2 2023$0.62$0.56 -$0.06$0.56$139.79M$134.22M

Harmony Biosciences Earnings - Frequently Asked Questions

Harmony Biosciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 5th, 2025 based off last year's report dates. Learn more on HRMY's earnings history.

Harmony Biosciences updated its FY 2025 earnings guidance on Tuesday, May, 6th. The company issued revenue guidance of $820.0 million-$860.0 million, compared to the consensus revenue estimate of $840.4 million.

In the previous quarter, Harmony Biosciences (NASDAQ:HRMY) reported $0.78 earnings per share (EPS) to beat the analysts' consensus estimate of $0.59 by $0.19. Learn more on analysts' earnings estimate vs. HRMY's actual earnings.

The conference call for Harmony Biosciences's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Harmony Biosciences's latest earnings report can be read online.
Read Transcript

Harmony Biosciences (NASDAQ:HRMY) has a recorded annual revenue of $744.85 million.

Harmony Biosciences (NASDAQ:HRMY) has a recorded net income of $128.85 million. HRMY has generated $2.62 earnings per share over the last four quarters.

Harmony Biosciences (NASDAQ:HRMY) has a trailing price-to-earnings ratio of 16.88 and a forward price-to-earnings ratio of 14.66. The price/earnings-to-growth ratio is 0.47.

Harmony Biosciences's earnings are expected to grow from $2.43 per share to $3.11 per share in the next year, which is a 27.98% increase.

More Earnings Resources from MarketBeat



This page (NASDAQ:HRMY) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners